Reihe: "FSS diskutiert...."

Mittwoch, 5. Mai 2021, 18:30 Uhr, online, in englischer Sprache

SUZANNE TURNER, University of Cambridge

„FSS discusses...."Spinning the roulette wheel of cancer; do implants and synthetic materials tip the odds in favour of cancer?" Vortrag circa 45 min, anschließende Diskussion

Moderation: Univ.-Prof. Dr. Lukas Kenner

Link zum Video

Abstract: Cancer develops in a multi-step process whereby sequential accumulation of damage to our DNA can lead to mutations in important genes that control cellular proliferation and differentiation. The acquisition of mutations can be a random process with some resulting from inherent biological processes such as cellular metabolism and DNA replication, with others being a consequence of exposure to carcinogens. There are many known cancer risk associations including, for example, smoking with lung cancer, exposure to sunlight with skin cancer, and consumption of certain dietary elements with colorectal cancer. However, we have all heard of someone who has smoked for 50 years but has not developed cancer. Herein lies the randomness of cancer development and perhaps the ‘good luck’ of some. However, what is clear is that we can reduce our cancer risk by shifting the odds and living a healthy lifestyle although, cancer may still occur. The key is to be informed of, and know the risks associated with cancer, so that we can actively shift the balance away from this disease. The risk of cancer that is associated with exposure to various environmental agents is largely unknown with many not presenting as obvious carcinogens that damage our DNA. There is also the issue of the dosage of a cancer-causing agent to which we are exposed, with higher levels perhaps putting the exposed at an increased risk of developing mutations in key genes and developing cancer. Many compounds are considered inert and not to be a cancer risk, although while not directly causing DNA damage, they may illicit a reaction in the body that does. Cancer development will be discussed in the context of breast implants, specifically breast implant associated anaplastic large cell lymphoma (BIA-ALCL), a cancer of the immune system. BIA-ALCL occurs in women regardless of the reason for breast implant use, whether it be for aesthetic reasons or reconstruction of the breast following breast cancer removal. How these ‘inert’ foreign objects when placed in the body cause cancer is a subject of much discussion amongst regulatory agents, manufacturers, patients, clinicians and surgeons, and will be presented and discussed in the context of why cancer develops in this talk.

Suzanne Turner Suzanne obtained her PhD in 1999 from the world-renowned Paterson Institute for Cancer Research and the Christie Hospital in Manchester where she examined the potential toxic side-effects of chemoprotective gene therapy. This work was a collaborative effort with what was at that time the AstraZeneca Central Toxicology Labs at Alderley Edge. Following this training period Suzanne moved to a research post, firstly at AstraZeneca Central Toxicology Labs and then at the Babraham Institute in Cambridge where under the guidance of Dr Denis Alexander she began to investigate mechanisms of Lymphomagenesis, a subject that she has pursued to become a world-expert in paediatric lymphomas, specifically Anaplastic Large Cell Lymphoma (ALCL). For the past 16 years Suzanne has been leading an academic research group at the University of Cambridge within the Department of Pathology and based at the Addenbrooke’s Hospital campus in Cambridge. It is here that Suzanne and her team are conducting academic research of an international standard. Suzanne also teaches aspects of the medical, veterinary and natural science tripos at Cambridge University and is the chair for graduate education in the department of pathology. In 2007, Suzanne was awarded the prestigious Leukaemia and Lymphoma Research (LLR; now Blood cancer UK) Bennett Fellowship and in 2012 a further 5-year Blood Cancer UK fellowship. Amongst her achievements are the inception and establishment of the European Research Initiative on ALCL, a study group that brings together scientists from across Europe to foster collaboration and advancement in this important area of health research. Suzanne is also the lead of ‘ALKATRAS’, a European Union Marie Curie Innovative Training Network of 14 research groups in 7 EU countries, non-clinical chair of the European Inter-Group for Collaboration into Childhood Non-Hodgkin Lymphoma (EICNHL), co-chair of the Cancer Research UK (CRUK) Cambridge Centre Paediatric Programme and biological lead for the National Cancer Research Institute (NCRI) paediatric lymphoma Clinical Study Group (CSG). Amongst her other interests Suzanne is the scientific advisor to the Alex Hulme Foundation and Francesca Richardson Trust. She is also a member of both the American and British Associations for Cancer Research (AACR/BACR), the Children’s Cancer and Leukaemia Group (CCLG) in the UK and the International Society for Paediatric Oncology (SIOP). She sits on the scientific committee of the European arm of the International society for paediatric oncology (SIOP-E) and is an invited expert member of the Medicines and Healthcare products Regulatory Agency (MHRA) plastics reconstructive, aesthetic surgery expert advisory group (PRASEAG) and the European Union Scientific Committee on Health Environmental and Emerging Risks (SCHEER) committee on breast implants and cancer risk.